Trecondi
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Treosulfan
- Made by
- medac Gesellschaft für klinische Spezialpräparate mbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (GRAFAPEX). It describes the substance, not this exact product.
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Treosulfan is an alkylating agent.
DNA alkylation is thought to be responsible for the cytotoxic activities of treosulfan.
A median of 42% of the treosulfan dose is excreted unchanged in the urine within 24 hours, and 89% of this unchanged fraction is excreted within the first 8 hours after administration.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-01-31
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | medac Gesellschaft für klinische Spezialpräparate mbH |
|---|---|
| Active substance | Treosulfan |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01AB02 · Cancer treatments and immune-system medicines |
| Authorised on | 2019-06-20 |
| Last updated by the regulator | 2026-02-17 |
| EMA product number | EMEA/H/C/004751 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).